Why the study?
Does intramuscular injection of a plasmid vector expressing human apolipoprotein E reduce atherosclerotic lesion coverage and xanthoma development in apoE-deficient mice?
Does intramuscular injection of a plasmid vector expressing human apolipoprotein E reduce atherosclerotic lesion coverage and xanthoma development in apoE-deficient mice?
Intramuscular gene transfer of human apoE2 limits the progression of atherosclerosis and xanthoma in apoE-deficient mice, demonstrating the therapeutic potential of ectopic muscle expression.
No takes yet. Share an insight, caveat, or question.
May support muscle-directed apoE gene therapy in models; leaves open human translation and safety.
Takis Athanasopoulos (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: